Oncotice (Bacillus Calmette-Guérin (Bcg), Tice)

Bacillus Calmette-Guérin (BCG) Tice, the active ingredient in Oncotice, is a live attenuated bacterial vaccine presented as a powder for intravesical use. It treats non‑muscle‑invasive bladder cancer in adults. GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oncotice is a live attenuated bacterial vaccine used in the management of bladder cancer, specifically targeting the urothelial carcinoma pathway.

- Non‑muscle‑invasive bladder cancer (NMIBC): Reduces the risk of tumour recurrence and progression. - Carcinoma in situ (CIS) of the bladder: Provides local immune‑mediated tumour control. - High‑risk NMIBC after transurethral resection: Serves as adjuvant therapy to decrease recurrence rates.

Oncotice may cause a range of adverse reactions following intravesical administration.

Common Side Effects: - Mild cystitis‑like symptoms: dysuria, frequency, urgency. - Low‑grade fever and chills. - Hematuria or mild bladder irritation. - Flu‑like symptoms such as fatigue and myalgia. - Localized pain at the instillation site.

Serious or Rare Side Effects: - Systemic BCG infection (disseminated BCGitis). - Severe allergic reactions including anaphylaxis. - Persistent high‑grade fever or sepsis. - Significant hematuria requiring intervention. - Renal impairment secondary to obstructive uropathy.

Before using Oncotice, clinicians should evaluate patient suitability and monitor for adverse events.

- Contraindication: Active urinary tract infection: Delay treatment until infection resolves. - Immunocompromised status: Increased risk of systemic infection; assess risk‑benefit. - Prior BCG therapy complications: Consider alternative strategies if severe reactions occurred. - Pregnancy: Avoid use; potential fetal risk not established. - Breastfeeding: Not recommended due to unknown excretion in milk. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Oncotice may interact with other agents that modify immune function or cause overlapping toxicities.

Major Interactions (Avoid): - Systemic immunosuppressants (e.g., high‑dose corticosteroids, azathioprine): May diminish BCG efficacy and increase infection risk. - Live vaccines administered concurrently: Risk of additive infection.

Moderate Interactions (Monitor Closely): - Antifungal agents such as fluconazole: May affect BCG metabolism indirectly. - Intravesical chemotherapy agents given in close succession: Potential for increased bladder irritation. - Cytokine‑targeting therapies (e.g., anti‑TNF agents): May alter immune response to BCG. - NSAIDs: May mask fever, a key safety signal. - Anticoagulants: Heightened risk of hematuria.